NCT02249351View on ClinicalTrials.gov

Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer Type

PHASE2TerminatedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 31, 1999

Primary Completion Date

May 31, 2000

Conditions
Alzheimer Disease
Interventions
DRUG

Talsaclidine

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02249351 - Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer Type | Biotech Hunter | Biotech Hunter